Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (253)	1/11/2007 12:55:32 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

GHDX--have not followed them. GLGC's net tangible assets are greater and the company has a longer history. But the water is better in California, and Gene Logic must have been stifled by that east coast humidity and proximity to NIH. Remember the Flow Thru Chip, spun out to Metrigenix in 2001. Apparently glgc still has a half stake in that company and they may have a product biomedcentral.com With higher throughput and improved performance this microarray platform has the potential to be a valuable tool for rapid routine gene expression profiling. Sounds like it has been a long haul developing the flow thru chip into something--so I am glad GLGC spun that off. And now CRO is gone, and what is left, the drug repositioning, their best and only play--and whether it is paired with a Perlegen and loosed upon Wall Street, who can say. At first glance, I wouldn't leap into GHDX with that marketcap of $600M.